Skip to main content

Advertisement

SpringerLink
Log in

Osteonecrosis of the femoral head: treatment with ancillary growth factors

  • Modern Surgical Treatment of Hip Avascular Necrosis (MA Mont, Section Editor)
  • Published:
Current Reviews in Musculoskeletal Medicine Aims and scope Submit manuscript

Abstract

Osteonecrosis (ON) of the femoral head, also known as avascular necrosis (AVN) of the femoral head, is a progressive disease that predominantly affects younger patients. During early stage of ON, decompression of the femoral head has been commonly used to improve pain. The decompression has been augmented with nonvascularized or vascularized bone grafts, mesenchymal stems cells, and growth factors. The use of adjuvant growth factors to supplement the core decompression has mainly been limited to animal models in an attempt to regenerate the necrotic lesion of ON. Factors utilized include bone morphogenetic proteins, vascular endothelial growth factors, hepatocyte growth factors, fibroblast growth factors, granulocyte colony-stimulating factors, and stem cells factors. In animal models, the use of these factors has been shown to increase bone formation and angiogenesis. Although promising, the use of these growth factors and cell-based therapies clinically remains limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently have been highlight as: • Of importance

  1. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg. 1995;77(3):459–74. American volume.

    CAS  PubMed  Google Scholar 

  2. Mont, M.A., et al. Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop Relat Res. 1998(355 Suppl):p. S314-35.

  3. Lavernia CJ, Sierra RJ, Grieco FR. Osteonecrosis of the femoral head. J Am Acad Orthop Surg. 1999;7(4):250–61.

    CAS  PubMed  Google Scholar 

  4. Mont MA et al. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg. 2010;92(12):2165–70. American volume. A systematic literature review by Mont suggests that even patients with asymptomatic osteonecrosis has a high rate of progression, and eventually leads to femoral head collapse. In comparing the location and size of lesions, small medial based lesions has a low rate of progression. Medium- and large-sized lesions have a high rate of progression to collapse. From this review the authors recommended joint-preserving surgery for the treatment of medium- and large-lesions even in the asymptomatic lesions.

  5. Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg. 1985;67(1):3–9. British volume.

    CAS  Google Scholar 

  6. Bozic KJ, Zurakowski D, Thornhill TS. Survivorship analysis of hips treated with core decompression for nontraumatic osteonecrosis of the femoral head. J Bone Joint Surg. 1999;81(2):200–9. American volume.

    CAS  PubMed  Google Scholar 

  7. Ito H et al. Mid-term prognosis of non-traumatic osteonecrosis of the femoral head. J Bone Joint Surg. 2003;85(6):796–801. British volume.

    CAS  Google Scholar 

  8. Hernigou P, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle-cell disease. J Bone Joint Surg. 2003;85-A(3):500–4. American volume.

    CAS  PubMed  Google Scholar 

  9. Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg. 1995;77(1):34–41. British volume.

    CAS  Google Scholar 

  10. Lafforgue P et al. Early-stage avascular necrosis of the femoral head: MR imaging for prognosis in 31 cases with at least 2 years of follow-up. Radiology. 1993;187(1):199–204.

    Article  CAS  PubMed  Google Scholar 

  11. Beltran J et al. Core decompression for avascular necrosis of the femoral head: correlation between long-term results and preoperative MR staging. Radiology. 1990;175(2):533–6.

    Article  CAS  PubMed  Google Scholar 

  12. Ha YC et al. Prediction of collapse in femoral head osteonecrosis: a modified Kerboul method with use of magnetic resonance images. J Bone Joint Surg. 2006;88 Suppl 3:35–40. American volume.

    Article  PubMed  Google Scholar 

  13. Southwood LL et al. Evaluation of Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J Orthop Res: Off Publ Orthop Res Soc. 2004;22(1):66–72.

    Article  CAS  Google Scholar 

  14. Baltzer AW et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther. 2000;7(9):734–9.

    Article  CAS  PubMed  Google Scholar 

  15. Miyazaki M et al. The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Spinal Disord Tech. 2008;21(5):372–9.

    Article  PubMed  Google Scholar 

  16. Roedersheimer M et al. A bone-derived mixture of TGF beta-superfamily members forms a more mature vascular network than bFGF or TGF-beta 2 in vivo. Angiogenesis. 2005;8(4):327–38.

    Article  CAS  PubMed  Google Scholar 

  17. Jones AL et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg. 2006;88(7):1431–41. American volume.

    Article  PubMed  Google Scholar 

  18. Reddi AH. Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg. 2001;83-A(Suppl 1(Pt 1)):S1–6. American volume.

    PubMed  Google Scholar 

  19. Wang W et al. The effect of core decompression on local expression of BMP-2, PPAR-gamma and bone regeneration in the steroid-induced femoral head osteonecrosis. BMC Musculoskelet Disord. 2012;13:142.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Lieberman JR, Conduah A, Urist MR. Treatment of osteonecrosis of the femoral head with core decompression and human bone morphogenetic protein. Clin Orthop Relat Res. 2004;429:139–45. 15 patients (17 hips) with osteonecrosis of the femoral head were treated with core decompression along with allogenic fibular bone graft and 50 mg of human bone morphogenetic protein (BMP). 16 hips were precollapse, and 1 had collapse. Treatment was successful in a majority of patients with precollapse disease.  The patients that were found to progress had larger lesions (>50% of the femoral head, and a greater proportion of involvement of the weight bearing surface).  The authors felt that further studies were needed to continue to translate this data to clinical practice.

  21. Mont MA et al. Strut-autografting with and without osteogenic protein-1: a preliminary study of a canine femoral head defect model. J Bone Joint Surg. 2001;83-A(7):1013–22. American volume.

    CAS  PubMed  Google Scholar 

  22. Tang TT et al. Treatment of osteonecrosis of the femoral head with hBMP-2-gene-modified tissue-engineered bone in goats. J Bone Joint Surg. 2007;89(1):127–9. British volume.

    Article  CAS  Google Scholar 

  23. Kim HK et al. Local administration of bone morphogenetic protein-2 and bisphosphonate during non-weight-bearing treatment of ischemic osteonecrosis of the femoral head: an experimental investigation in immature pigs. J Bone Joint Surg. 2014;96(18):1515–24. American volume. In a pig model for osteonecrosis Kim found that the administration of BMP-2 along with a bisphosphonate decreased bone resorption and increased new bone formation. During treatment, the pigs were kept non-weight-bearing.  The injection of the BMP product was through the hip joint and it was noted that heterotopic ossification was a complication.

  24. Wang CK et al. Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone. Biomaterials. 2009;30(25):4178–86.

    Article  CAS  PubMed  Google Scholar 

  25. Sun W et al. Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. PLoS ONE. 2014;9(6):e100424. In a clinical study using human bone morphogenetic protein-2 (rhBMP-2) and bone-grafting through a trapdoor procedure to treat osteonecrosis of the femoral head. rhBMP-2 was combined with an artificial bone substitue. A majority of patients had excellent and good results based on the Harris Hip Score. Worse results were seen in patients with collapse of the femoral head.

  26. Urist MR. Bone: formation by autoinduction. Science. 1965;150(3698):893–9.

    Article  CAS  PubMed  Google Scholar 

  27. Vandermeer JS et al. Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity. J Bone Joint Surg. 2011;93(10):905–13. American volume.

    Article  PubMed  Google Scholar 

  28. Shields LB et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine. 2006;31(5):542–7 (Phila Pa 1976).

    Article  PubMed  Google Scholar 

  29. Govender S et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg. 2002;84-A(12):2123–34. American volume.

    PubMed  Google Scholar 

  30. Mazieres B. Bone morphogenetic protein and bone necrosis: a perspective. ARCO News Lett. 1994;6:3–5.

    Google Scholar 

  31. Pan ZX et al. Effect of recombinant human bone morphogenetic protein 2/poly-lactide-co-glycolic acid (rhBMP-2/PLGA) with core decompression on repair of rabbit femoral head necrosis. Asian Pac J Trop Med. 2014;7(11):895–9.

    Article  CAS  PubMed  Google Scholar 

  32. Simank HG et al. Bone morphogenetic protein-2 and growth and differentiation factor-5 enhance the healing of necrotic bone in a sheep model. Growth Factors. 2001;19(4):247–57.

    Article  CAS  PubMed  Google Scholar 

  33. Aya-ay J et al. Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head. J Bone Miner Res. 2007;22(1):93–100.

    Article  CAS  PubMed  Google Scholar 

  34. Kim HK et al. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg. 2005;87(3):550–7. American volume.

    PubMed  Google Scholar 

  35. Dai KR et al. Repairing of goat tibial bone defects with BMP-2 gene-modified tissue-engineered bone. Calcif Tissue Int. 2005;77(1):55–61.

    Article  CAS  PubMed  Google Scholar 

  36. Lieberman JR et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg. 1999;81(7):905–17. American volume.

    CAS  PubMed  Google Scholar 

  37. Wang JC et al. Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Bone Joint Surg. 2003;85-A(5):905–11. American volume.

    PubMed  Google Scholar 

  38. Fu YC et al. Optimized bone regeneration based on sustained release from three-dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2. Biotechnol Bioeng. 2008;99(4):996–1006.

    Article  CAS  PubMed  Google Scholar 

  39. Ho ML et al. Controlled release carrier of BSA made by W/O/W emulsion method containing PLGA and hydroxyapatite. J Control Release. 2008;128(2):142–8.

    Article  CAS  PubMed  Google Scholar 

  40. Seyler TM et al. Nonvascularized bone grafting defers joint arthroplasty in hip osteonecrosis. Clin Orthop Relat Res. 2008;466(5):1125–32.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Martin JR, Houdek MT, Sierra RJ. Use of concentrated bone marrow aspirate and platelet-rich plasma during minimally invasive decompression of the femoral head in the treatment of osteonecrosis. Croat Med J. 2013;54(3):219–24. In a study of 77 patients were treated with minimally invasive iliac crest bone marrow aspirations supplemented with platelet rich plasma in pre-collapse osteonecrosis of the femoral head.  Significant pain relief was reported in 86% of patients. There were no significant complications in any patient. Sixteen hips (21%) progressed to further stages of osteonecrosis, requiring total hip replacement. This procedure provided significant pain relief and halted the progression of disease in a majority of patients.

  42. Nakamura Y et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens. 1996;14(9):1067–72.

    Article  CAS  PubMed  Google Scholar 

  43. Nakamura Y et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension. 1996;28(3):409–13.

    Article  CAS  PubMed  Google Scholar 

  44. Wen Q et al. Treatment of avascular necrosis of the femoral head by hepatocyte growth factor-transgenic bone marrow stromal stem cells. Gene Ther. 2008;15(23):1523–35.

    Article  CAS  PubMed  Google Scholar 

  45. Wen Q, Dan J., Zhou C-Y, Zhou M-Q, Luo W, Ma L. HGF-Transgenic MSCs can improve the effects of tissue self-repair in a rabbit model of traumatic osteonecrosis of the femoral head. PLoS ONE. 2012. 75(5). In a rabbit model of early stage osteonecrosis, transgenic hepatocyte growth factor mesenchymal stem cells were transplanted into the area of necrosis. The authors noted self-repair of the lesions and an increase expression of vascular endothelial growth factors.

  46. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611.

    Article  CAS  PubMed  Google Scholar 

  47. Gao YS et al. A novel rat model of osteonecrosis of the femoral head induced by periarticular injection of vascular endothelial growth factor receptor 2 antibody. J Surg Res. 2013;183(1):e1–5.

    Article  CAS  PubMed  Google Scholar 

  48. Yang C et al. Vascular endothelial growth factor gene transfection to enhance the repair of avascular necrosis of the femoral head of rabbit. Chin Med J (Engl). 2003;116(10):1544–8.

    CAS  Google Scholar 

  49. Yang C et al. Experimental study of vascular endothelial growth factor gene therapy for avascular necrosis of the femoral head. J Huazhong Univ Sci Technol Med Sci. 2003;23(3):297–9. 316.

    Article  CAS  PubMed  Google Scholar 

  50. Cao K et al. Deproteinized bone with VEGF gene transfer to facilitate the repair of early avascular necrosis of femoral head of rabbit. Chin J Traumatol. 2009;12(5):269–74.

    CAS  PubMed  Google Scholar 

  51. Liu YG et al. Effect of vascular endothelial growth factor 121 adenovirus transduction in rabbit model of femur head necrosis. J Trauma. 2011;70(6):1519–23.

    Article  CAS  PubMed  Google Scholar 

  52. Hang D et al. Treatment of osteonecrosis of the femoral head with VEGF165 transgenic bone marrow mesenchymal stem cells in mongrel dogs. Cells Tissues Organs. 2012;195(6):495–506.

    Article  CAS  PubMed  Google Scholar 

  53. Zou D et al. In vitro study of enhanced osteogenesis induced by HIF-1alpha-transduced bone marrow stem cells. Cell Prolif. 2011;44(3):234–43.

    Article  CAS  PubMed  Google Scholar 

  54. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129(3):465–72. In this article the authors overview the activity of the hypoxia inducible factors (HIFs) and its pro-angiogenic and pro-glycolysis pathways. Recently reports of “cancer stem cells” have been linked to these factors and responsible for the self-renewal, and tumour growth.This highlights the role of hypoxia, and how it can induce angiogenesis.

  55. Riddle RC et al. Role of hypoxia-inducible factor-1alpha in angiogenic-osteogenic coupling. J Mol Med. 2009;87(6):583–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Kim HK et al. Hypoxia and HIF-1alpha expression in the epiphyseal cartilage following ischemic injury to the immature femoral head. Bone. 2009;45(2):280–8.

    Article  CAS  PubMed  Google Scholar 

  57. Zhang C et al. Regulation of VEGF expression by HIF-1alpha in the femoral head cartilage following ischemia osteonecrosis. Sci Rep. 2012;2:650.

    PubMed Central  PubMed  Google Scholar 

  58. Ding H et al. HIF-1alpha transgenic bone marrow cells can promote tissue repair in cases of corticosteroid-induced osteonecrosis of the femoral head in rabbits. PLoS ONE. 2013;8(5):e63628.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Izbicka E et al. Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Cancer Res. 1996;56(3):633–6.

    CAS  PubMed  Google Scholar 

  60. Yang C et al. Basic fibroblast growth factor gene transfection to enhance the repair of avascular necrosis of the femoral head. Chin Med Sci J. 2004;19(2):111–5.

    CAS  PubMed  Google Scholar 

  61. Wu X et al. A combination of granulocyte colony-stimulating factor and stem cell factor ameliorates steroid-associated osteonecrosis in rabbits. J Rheumatol. 2008;35(11):2241–8.

    Article  CAS  PubMed  Google Scholar 

  62. Wu X et al. G-CSF/SCF exert beneficial effects via anti-apoptosis in rabbits with steroid-associated osteonecrosis. Exp Mol Pathol. 2013;94(1):247–54. In a rabbit model of steroid-induced osteonecrosis, the authors found that treatment with G-CSF/SCF could inhibit the developement of osteonecrosis by inhibiting the expression of serum tartrate-resistant acid phosphatase (TRAP5b).

  63. Ulich TR et al. Hematologic effects of stem cell factor in vivo and in vitro in rodents. Blood. 1991;78(3):645–50.

    CAS  PubMed  Google Scholar 

  64. Boden SD et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 2002;27(23):2662–73.

    Article  PubMed  Google Scholar 

  65. Haid Jr RW et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J: Off J N Am Spine Soc. 2004;4(5):527–38. discussion 538–9.

    Article  Google Scholar 

  66. Bertone AL et al. Adenoviral-mediated transfer of human BMP-6 gene accelerates healing in a rabbit ulnar osteotomy model. J Orthop Res. 2004;22(6):1261–70.

    Article  CAS  PubMed  Google Scholar 

  67. Assessment of adenoviral vector safety and toxicity: report of the national institutes of health recombinant DNA advisory committee. Hum Gene Ther. 2002;13(1):3–13.

  68. Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669–72.

    Article  CAS  PubMed  Google Scholar 

  69. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Matthew T. Houdek and Cody C. Wyles declare that they have no conflict of interest.

Rafael J. Sierra reports personal fees from Biomet.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA

    Matthew T. Houdek & Rafael J. Sierra

  2. Mayo Clinic Medical School, 200 First St. SW, Rochester, MN, 55909, USA

    Cody C. Wyles

Authors
  1. Matthew T. Houdek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cody C. Wyles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rafael J. Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael J. Sierra.

Additional information

This article is part of the Topical Collection on Modern Surgical Treatment of Hip Avascular Necrosis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Houdek, M.T., Wyles, C.C. & Sierra, R.J. Osteonecrosis of the femoral head: treatment with ancillary growth factors. Curr Rev Musculoskelet Med 8, 233–239 (2015). https://doi.org/10.1007/s12178-015-9281-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12178-015-9281-z

Keywords

Search

Navigation